Noninvasive vagus nerve stimulation to reduce ileus after major colorectal surgery: early development study

• Published in: Colorectal disease Vol. 23; no. 5; pp. 1225 - 1232
• Main Authors: Chapman, Stephen J., Helliwell, Jack A., Naylor, Maureen, Tassinari, Cerys, Corrigan, Neil, Jayne, David G.
• Format: Journal Article
• Language: English
• Published: England Wiley Subscription Services, Inc 01.05.2021
• Subjects: Adverse events; Colorectal Surgery; Compliance; Digestive System Surgical Procedures; Humans; ileus; Ileus - etiology; Ileus - prevention & control; Intestine; Malignancy; noninvasive vagus nerve stimulation; Patients; Surgery; Treatment Outcome; Usability; Vagus nerve; Vagus Nerve Stimulation - adverse effects; vagus nerve; ileus; noninvasive vagus nerve stimulation; surgery
• ISSN: 1462-8910; 1463-1318; 1463-1318
• DOI: 10.1111/codi.15561

Aim Vagus nerve stimulation has emerged as a plausible intervention to reduce ileus after surgery. An early development study was undertaken with the aim of exploring the feasibility of self‐administered, noninvasive vagus nerve stimulation (nVNS) after major colorectal surgery. Method A parallel‐group, randomized controlled trial was undertaken between 1 January 2018 and 31 August 2019. Forty patients undergoing colorectal surgery for malignancy were allocated equally to Sham and Active stimulation groups. Electrical vagus nerve stimulation was self‐administered bilaterally over the cervical surface landmarks for 5 days before and after surgery. Outcomes of interest were postoperative complications and adverse events measured using the Clavien–Dindo scale, treatment compliance, device usability according to the Systems Usability Scale (SUS) and clinical measures of bowel recovery. Results Forty patients were randomized and one withdrew, leaving 39 for analysis. Postoperative complications occurred in 9/19 (47.4%) participants receiving Sham and 11/20 (55.0%) receiving Active stimulation and were mostly minor. Compliance with treatment before surgery was 4.7 ± 0.9 days out of 5 days in the Sham group and 4.7 ± 1.1 in the Active group. Compliance with treatment after surgery was 4.1 ± 1.1 and 4.4 ± 1.5, respectively. Participants considered the intervention to be ‘acceptable’ according to the SUS. The most prominent differences in bowel recovery were days to first flatus (2.35 ± 1.32 vs 1.65 ± 0.88) and tolerance of solid diet (2.18 ± 2.21 vs 1.75 ± 0.91) for Sham and Active groups, respectively. Conclusion This study supports the safety, treatment compliance and usability of self‐administered nVNS in patients undergoing major colorectal surgery.